Bet on an effective player: 9 reasons why you should use ramipril Review article
Article Sidebar
Published:
Sep 30, 2021
Keywords:
angiotensin-converting enzyme inhibitors, ramipril, arterial hypertension, cardiovascular risk
Main Article Content
Abstract
Angiotensin-converting enzyme inhibitors still form the basis of modern cardiovascular pharmacotherapy. Ramipril has a special place in this important drug class. This paper lists the main reasons why ramipril is often the natural choice in the population ofpatients with multiple cardiovascular diseases.
Downloads
Download data is not yet available.
Article Details
How to Cite
Grabysa , M., & Grabysa , R. (2021). Bet on an effective player: 9 reasons why you should use ramipril. Cardiology in Practice, 15(1-2), 5-10. Retrieved from https://journalsmededu.pl/index.php/kwp/article/view/1492
Issue
Section
Pharmacology in cardiological practice
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Braunwald E. Cardiovascular pharmacology: a look back and a glimpse into the future. Eur Heart J Cardiovasc Pharmacother. 2015; 1: 7-9.
2. Williams B, Mancia G, Desormais I et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. J Hypertens. 2018; 36: 1953-2041.
3. Tykarski A, Filipiak KJ, Januszewicz A et al. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce. 2019, 5: 1-86.
4. Yusuf S, Sleight P, Pogue J et al. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3): 145-53.
5. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000; 355(9200): 253-9.
6. Bosch J, Lonn E, Pogue J et al. HOPE/HOPE-TOO Study Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation. 2005; 112(9): 1339-46.
7. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993; 342(8875): 821-8.
8. Bosch J, Yusuf S, Pogue J et al. HOPE Investigators. Heart outcomes prevention evaluation. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002; 324(7339): 699-702.
9. Kaplan NM. on Behalf of the Clinical Altace Real-World Efficacy (CARE) Investigators. The CARE Study: A Postmarketing Evaluation of Ramipril in 11.100 Patients. Clin Ther. 1996; 18: 658-70.
10. Agabiti-Rosei E, Ambrosioni E, Dal Palu C et al. ACE inhibitor ramipril is more effective than beta-bloker atenolol in reducing left ventricular mass in hypertension. Results of the RACE study on the behalf of the RACE study group. J Hypertens. 1995; 13(11): 1325-34.
11. Lonn EM, Yusuf S, Dzavik V et al. Effect of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001; 103: 919-25.
12. Szczepaniak-Chicheł L. Inhibitor konwertazy angiotensyny. In: Grodzicki T, Narkiewicz K, Czarnecka D et al. Hipertensjologia. Podręcznik Polskiego Towarzystwa Nadciśnienia Tętniczego. Vol 1. Via Medica, Gdańsk 2016.
13. Pilote L, Abrahamowicz M, Rodrigues E et al. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med. 2004; 141: 102-12.
14. Wełnicki A. 10 powodów, dla których warto stosować ramipril. Medycyna Faktów 2017; 3(36): 276-80.
15. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997; 349: 1857-63.
16. Zou X, Chen K, Zou J et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020.
17. Klocek M, Jankowski P, Czarnecka D. Układ renina-angiotensyna-aldosteron. In: Grodzicki T, Narkiewicz K, Czarnecka D et al. Hipertensjologia.cPodręcznik Polskiego Towarzystwa Nadciśnienia Tętniczego. Vol 1. Via Medica, Gdańsk 2016.
18. Soler MJ, Barrios C, Oliva R et al. Pharmacologic modulation of ACE2 expression. Curr Hypertens Rep. 2008; 10: 410-14.
19. Mehra MR, Desai SS, Kuy S et al. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020; 382: e102. http://doi.org/10.1056/NEJMoa2007621.
20. Amat-Santos IJ, Santos-Martinez S, Lopez-Otero D et al. Ramipril in High-Risk Patients With COVID-19. J Am Coll Cardiol. 2020; 76(3): 268-76.
2. Williams B, Mancia G, Desormais I et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. J Hypertens. 2018; 36: 1953-2041.
3. Tykarski A, Filipiak KJ, Januszewicz A et al. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce. 2019, 5: 1-86.
4. Yusuf S, Sleight P, Pogue J et al. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3): 145-53.
5. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000; 355(9200): 253-9.
6. Bosch J, Lonn E, Pogue J et al. HOPE/HOPE-TOO Study Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation. 2005; 112(9): 1339-46.
7. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993; 342(8875): 821-8.
8. Bosch J, Yusuf S, Pogue J et al. HOPE Investigators. Heart outcomes prevention evaluation. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002; 324(7339): 699-702.
9. Kaplan NM. on Behalf of the Clinical Altace Real-World Efficacy (CARE) Investigators. The CARE Study: A Postmarketing Evaluation of Ramipril in 11.100 Patients. Clin Ther. 1996; 18: 658-70.
10. Agabiti-Rosei E, Ambrosioni E, Dal Palu C et al. ACE inhibitor ramipril is more effective than beta-bloker atenolol in reducing left ventricular mass in hypertension. Results of the RACE study on the behalf of the RACE study group. J Hypertens. 1995; 13(11): 1325-34.
11. Lonn EM, Yusuf S, Dzavik V et al. Effect of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001; 103: 919-25.
12. Szczepaniak-Chicheł L. Inhibitor konwertazy angiotensyny. In: Grodzicki T, Narkiewicz K, Czarnecka D et al. Hipertensjologia. Podręcznik Polskiego Towarzystwa Nadciśnienia Tętniczego. Vol 1. Via Medica, Gdańsk 2016.
13. Pilote L, Abrahamowicz M, Rodrigues E et al. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med. 2004; 141: 102-12.
14. Wełnicki A. 10 powodów, dla których warto stosować ramipril. Medycyna Faktów 2017; 3(36): 276-80.
15. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997; 349: 1857-63.
16. Zou X, Chen K, Zou J et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020.
17. Klocek M, Jankowski P, Czarnecka D. Układ renina-angiotensyna-aldosteron. In: Grodzicki T, Narkiewicz K, Czarnecka D et al. Hipertensjologia.cPodręcznik Polskiego Towarzystwa Nadciśnienia Tętniczego. Vol 1. Via Medica, Gdańsk 2016.
18. Soler MJ, Barrios C, Oliva R et al. Pharmacologic modulation of ACE2 expression. Curr Hypertens Rep. 2008; 10: 410-14.
19. Mehra MR, Desai SS, Kuy S et al. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020; 382: e102. http://doi.org/10.1056/NEJMoa2007621.
20. Amat-Santos IJ, Santos-Martinez S, Lopez-Otero D et al. Ramipril in High-Risk Patients With COVID-19. J Am Coll Cardiol. 2020; 76(3): 268-76.